ELTX — Elicio Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1601485 ·
Last close
$2.98
Market Cap
$78.32M
52W High
$16.00
52W Low
$2.66
ADV30
338,132
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -10,602,000 | -11,823,000 | 22,689,000 | 14,948,000 | 24,126,000 |
| Dec 2025 | 0 | — | -8,842,000 | -7,718,000 | 25,862,000 | 18,563,000 | 24,226,000 |
| Sep 2025 | 0 | — | -8,045,000 | -10,083,000 | 28,284,000 | 20,611,000 | 24,468,000 |
| Jun 2025 | 0 | — | -9,676,000 | -10,561,000 | 29,528,000 | 22,088,000 | 27,694,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,478,000
Investing CF
$-16,000
Financing CF
$34,394,000
CapEx
$-45,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-245,495,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-38,821,000
Pretax Income TTM
$-40,185,000
Interest Exp TTM
$1,364,000
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,299,000 | -39,571,000 | 25,862,000 | 24,226,000 | — | -36,952,000 |
| Dec 2024 | 0 | -44,986,000 | -51,898,000 | 28,178,000 | 39,490,000 | — | -37,068,000 |
| Dec 2023 | 0 | -35,745,000 | -35,195,000 | 27,146,000 | 15,773,000 | — | -32,694,000 |
| Dec 2022 | 0 | -23,733,000 | -28,208,000 | 22,664,000 | 124,809,000 | — | -22,179,000 |
TTM Snapshot
Revenues TTM
$6,683,000
NetIncome TTM
$-52,398,000
OpCashFlow TTM
$0
Assets (Latest)
$28,178,000
Forward EPS
$-2.17
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.98 · call volume: 122 · put volume: 5
Expected Move to 2026-11-20:
±$1.76
(59.06%) —
implied range
$1.22 –
$4.74
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTOR | CITIUS ONCOLOGY, INC. | $79.32M | $0.75 | — |
| ZOMDF | Zomedica Corp. | $80.06M | $0.08 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $80.47M | $1.17 | — |
| MNOV | MEDICINOVA INC | $75.31M | $1.53 | — |
| MAIA | MAIA Biotechnology, Inc. | $82.11M | $1.35 | — |
News headlines (Yahoo Finance, 1h cache)
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
2026-08-24 12:00 · Yahoo
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
2026-07-02 04:25 · Yahoo
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
2026-06-29 12:00 · Yahoo
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
2026-06-17 12:00 · Yahoo
Top Midday Decliners
2026-06-15 18:01 · Yahoo
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
2026-06-15 11:00 · Yahoo
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
2026-06-01 12:00 · Yahoo
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-11 20:05 · Yahoo
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
2026-04-30 12:00 · Yahoo
Elicio Therapeutics Reports Inducement Grants
2026-04-16 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.